Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pemphigus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Pemphigus. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-001217-33 Sponsor Protocol Number: CVAY736X2203 Start Date*: 2013-11-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris
    Medical condition: Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002917-16 Sponsor Protocol Number: ARGX-113-1905 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Pemphigus (ADDRESS+)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052802 Pemphigus vulgaris LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002146-37 Sponsor Protocol Number: INCB50465-208 Start Date*: 2019-01-24
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris
    Medical condition: Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004562-33 Sponsor Protocol Number: HHD_SCENESSE Start Date*: 2013-12-17
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS
    Medical condition: SYMPTOMATIC HHD PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10019029 Hailey-Hailey disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002261-19 Sponsor Protocol Number: PRN1008-012 Start Date*: 2018-12-12
    Sponsor Name:Principia Biopharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
    Medical condition: pemphigus vulgaris [PV] or pemphigus foliaceus [PF]
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    21.0 100000004858 10057054 Pemphigus foliaceous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005711-26 Sponsor Protocol Number: IDI-DER-1-20070930 Start Date*: 2007-11-15
    Sponsor Name:ISTITUTO DERMOPATICO IMMACOLATA
    Full Title: An open prospective, monocenter, consecutive non randomized clinical trial on therapy with monoclonal antibodies anti-CD20 in the treatment of pemphigus vulgare or foliaceus, serious and resistant ...
    Medical condition: Pemphigus vulgaris, pemphigus foliaceus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034280 Pemphigus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002333-40 Sponsor Protocol Number: ARGX-113-1701 Start Date*: 2018-01-31
    Sponsor Name:argenx BVBA
    Full Title: An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vul...
    Medical condition: Pemphigus (Vulgaris or Foliaceus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-000526-75 Sponsor Protocol Number: WX17796 Start Date*: 2006-02-06
    Sponsor Name:Aspreva pharmaceuticals Corporation
    Full Title: Estudio multicéntrico, prospectivo, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y 52 semanas de duración para evaluar la eficacia y la seguridad del micofen...
    Medical condition: Pénfigo vulgar
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052802 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000211-24 Sponsor Protocol Number: IMAT-PV Start Date*: 2013-10-01
    Sponsor Name:Ruprecht-Karls-University Heidelberg
    Full Title: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuva...
    Medical condition: patients with Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003564-37 Sponsor Protocol Number: PRN1008-005 Start Date*: 2016-04-21
    Sponsor Name:Principia Biopharma Australia Pty Ltd
    Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn...
    Medical condition: Pemphigus: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000373-80 Sponsor Protocol Number: DERM-101 Start Date*: 2018-05-24
    Sponsor Name:Dermecular Therapeutics, Inc.
    Full Title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or H...
    Medical condition: Darier’s Disease or Hailey-Hailey Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10011860 Darier's disease LLT
    20.1 100000004850 10019029 Hailey-Hailey disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000382-41 Sponsor Protocol Number: WA29330 Start Date*: 2015-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris
    Medical condition: Pemphigus Vulgaris (PV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001370-20 Sponsor Protocol Number: OPV116910 Start Date*: 2014-11-26
    Sponsor Name:Glaxo Group Ltd
    Full Title: OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris
    Medical condition: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) HR (Completed) GR (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001727-12 Sponsor Protocol Number: TPV11 Start Date*: 2019-10-24
    Sponsor Name:Topas Therapeutics GmbH
    Full Title: A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiven...
    Medical condition: Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000060-22 Sponsor Protocol Number: 2020/0424/HP Start Date*: 2023-04-03
    Sponsor Name:CHU de Rouen
    Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti...
    Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005266-31 Sponsor Protocol Number: 2008/068/HP Start Date*: 2009-02-06
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE C...
    Medical condition: Pemphogoide bulleuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001417-32 Sponsor Protocol Number: 2018/070/HP Start Date*: 2018-07-13
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation
    Medical condition: Patients with Bullous pemphigoid included in RITUXIMAB3 study
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004666-26 Sponsor Protocol Number: 2015/208/HP Start Date*: 2017-07-19
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid
    Medical condition: severe forms of mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001826-23 Sponsor Protocol Number: MMP-Clob1 Start Date*: 2023-05-31
    Sponsor Name:Dipartimento di Scienze della Salute dell'Università degli Studi di Firenze
    Full Title: A prospective, non controlled, phase 2 pilot study to assess the safety and efficacy of a new topical formulation of clobetasol 0.05% for mucosal use in patients with mucous membrane pemphigoid
    Medical condition: Mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004858 10004296 Benign mucous membrane pemphigoid without mention of ocular involvement LLT
    25.0 100000004858 10004294 Benign mucous membrane pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:42:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA